WebSep 1, 2024 · SAN DIEGO, Sept. 1, 2024 /PRNewswire/ -- Cue Health ("Cue") (Nasdaq: HLTH) today announced that it has made a de novo submission to the U.S. Food and Drug Administration (FDA) for full clearance of the Cue® Flu Molecular Test for at-home and point-of-care (POC) use. There are currently no flu tests on the market for home use. WebApr 11, 2024 · According to analysts' consensus price target of $7.00, Cue Health has a forecasted upside of 274.3% from its current price of $1.87. Amount of Analyst Coverage Cue Health has received no research coverage in the past 90 days. See Top Rated MarketRank™ Stocks Here About Cue Health (NASDAQ:HLTH) Stock
Cue Health Appoints Nitin Duggal as Chief Marketing Officer
WebPress release May 13, 2024 Cue Health Announces Completion of $235 Million Private Financing to Accelerate Growth Press release April 5, 2024 Cue Health Launches “Cue for Schools,” an On-Site Molecular Testing … WebSAN DIEGO, California, September 23, 2024– Cue Health Inc. (“Cue Health”) (Nasdaq: HLTH), a health technology company, today announced the pricing of its initial public … eastman flexsys
2024-04-12 NDAQ:CUE Press Release Cue Biopharma Inc.
WebMar 15, 2024 · Cue Health expects first quarter 2024 revenues in the range of $20 million to $25 million. About Cue Health. Cue is a healthcare technology company that makes it … WebFeb 2, 2024 · Cue Health’s New Suite of At-Home Diagnostic Tests and Expansion of Cue Care Puts You in Control of Your Health Mar 02, 2024 Cue Health Collaborates with … WebMar 22, 2024 · /PRNewswire/ -- Cue Health Inc. (Nasdaq: HLTH), a healthcare technology company, and Albertsons Companies (NYSE: ACI) today announced a first-of-its-kind... culture bacteria other test uses